An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI for Hyperthyroidism.
Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Dec 4, 2020
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hyperthyroid patients, either subclinical or overt, who have undergone RAI treatment in the period of 2005-2015.
- Exclusion Criteria:
- • Prior use of L-thyroxine
- • Prior thyroid surgery
- • Prior RAI treatment
- • Patients with thyroiditis
About Universitair Ziekenhuis Brussel
Universitair Ziekenhuis Brussel (UZ Brussel) is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution affiliated with the Vrije Universiteit Brussel, UZ Brussel integrates cutting-edge medical research with high-quality patient care. The hospital's multidisciplinary teams are dedicated to exploring novel therapeutic approaches and contributing to the development of evidence-based treatments, ensuring the highest standards of safety and efficacy in clinical research. With a strong focus on collaboration and knowledge dissemination, UZ Brussel plays a pivotal role in shaping the future of medicine and improving patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Patients applied
Trial Officials
Corina Andreescu, Doctorate
Principal Investigator
Universitair Ziekenhuis Brussel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials